Sema4 debuts genetic testing services
Stamford-headquartered Sema4 has introduced a line of genomic testing services and digital tools designed to aid oncologists treating cancer patients from the risk assessment to...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
Stamford-headquartered Sema4 has introduced a line of genomic testing services and digital tools designed to aid oncologists treating cancer patients from the risk assessment to...
Ann Nyberg of WTNH News 8 recently interviewed Dawn Hocevar, President & CEO of BioCT. Highlights: * The bioscience industry in Connecticut is making a...
Thetis Pharmaceuticals reports preclinical data supporting the potential of its lead candidate, TP-317, in inflammatory bowel disease (IBD). TP-317 is a novel salt of Resolvin...
Cybrexa Therapeutics reports preclinical data supporting the potential of its proprietary alphalex™ technology platform. Results from multiple preclinical studies demonstrate that alphalex™ successfully enables the combination...
Strategic Spaces is a leader in prefabricated construction for interior spaces and commercial furniture solutions. With a trained team of interior designers and construction project...
The world’s first gene therapy clinical trial for glygogen stoprage disease is underway at the Connecticut Children’s Medical Center and UConn Health, under the direction...
The world’s first gene therapy clinical trial for glygogen stoprage disease is underway at the Connecticut Children’s Medical Center and UConn Health, under the direction of...
Have you visited the BioCT Careers page recently? This enhanced, interactive site matches job seekers and employers in the bioscience industry throughout Connecticut. Job seekers...
Connecticut Innovations reports that it has closed on the initial $665,000 tranche of a $1 million investment in Invixium Access, a manufacturer of modern biometric solutions. Invixium was a winner...
SpringWorks Therapeutics reports that the first patient has been dosed in the Phase 3 “DeFi” (Desmoid/Fibromatosis) trial evaluating nirogacestat, an oral, selective, small molecule gamma-secretase...